Collegium Pharmaceutical (COLL) Stock Price, News & Analysis

Company Overview

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S. Food and Drug Administration (FDA) in 2016, and Apadaz® (hydrocodone bitartrate and acetaminophen) tablets. Collegium also markets Rybix® ODT (oxycodone), an orally disintegrating tablet, and has rights to the fentanyl transdermal system ONSOLIS® under a distribution agreement. These products are supported by a dedicated commercial organization and are primarily available in the United States.

Headquartered in Wilmington, North Carolina, Collegium maintains research, development and manufacturing operations, including a facility in Richmond, Virginia. Since its incorporation in 2013, the company has expanded its product portfolio and pursued a pipeline of additional abuse-deterrent drug candidates, seeking to address unmet needs in both acute and chronic pain treatment.

Collegium is led by a management team with experience in specialty pharmaceuticals and regulatory affairs. Michael Thomas serves as President and Chief Executive Officer, guiding the company’s strategic direction and commercial growth initiatives. Under this leadership, Collegium continues to advance its mission of improving patient safety and outcomes through innovative drug delivery technologies.

Key Stats

• Today's Range: $34.33 to $35.50
• 50-Day Range: $31.99 to $45.75
• 52-Week Range: $26.72 to $50.79
• Volume: 390,480 shs
• Average Volume: 499,905 shs
• Market Capitalization: $1.15 billion
• P/E Ratio: 20.68
• Dividend Yield: N/A
• Price Target: $53.40
• Consensus Rating: Moderate Buy

Collegium Pharmaceutical Stock Analysis - MarketRank™

Collegium Pharmaceutical scored higher than 53% of companies evaluated by MarketBeat, and ranked 439th out of 854 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Collegium Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Collegium Pharmaceutical has a consensus price target of $53.40, representing about 52.5% upside from its current price of $35.01.

Amount of Analyst Coverage

Collegium Pharmaceutical has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -16.77%

Earnings Growth

Earnings for Collegium Pharmaceutical are expected to decrease by -16.77% in the coming year, from $6.38 to $5.31 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Collegium Pharmaceutical is 20.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.55.

Price to Earnings Ratio vs. Sector

The P/E ratio of Collegium Pharmaceutical is 20.46, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.06.

Price to Book Value per Share Ratio

Collegium Pharmaceutical has a P/B Ratio of 3.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for COLL.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Collegium Pharmaceutical does not currently pay a dividend.

Dividend Growth

Collegium Pharmaceutical does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: N/A

News Sentiment

Collegium Pharmaceutical has a news sentiment score of -0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Collegium Pharmaceutical this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for COLL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Collegium Pharmaceutical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Collegium Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,507,572.00 in company stock.

Percentage Held by Insiders

1.85% of the stock of Collegium Pharmaceutical is held by insiders.

Percentage Held by Institutions

Collegium Pharmaceutical has minimal institutional ownership at this time.

COLL Stock Analysis - Frequently Asked Questions

How have COLL shares performed this year?

Collegium Pharmaceutical's stock was trading at $46.30 at the start of the year. Since then, COLL shares have decreased by 24.4% and is now trading at $35.0140.

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) issued its quarterly earnings data on Thursday, February, 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by $0.16. The business's revenue was up 12.9% on a year-over-year basis.
Read the conference call transcript.

How will Collegium Pharmaceutical's stock buyback program work?

Collegium Pharmaceutical's board initiated a share buyback plan on Monday, July 7th 2025, which authorizes the company to repurchase $150,000,000 in outstanding shares, according to EventVestor. This means that the company could repurchase up to 15.4% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its shares are undervalued.

When did Collegium Pharmaceutical IPO?

Collegium Pharmaceutical (COLL) raised $75 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Who are Collegium Pharmaceutical's major shareholders?

Collegium Pharmaceutical's top institutional shareholders include Principal Financial Group Inc. (4.00%), Emerald Advisers LLC (1.24%), Assenagon Asset Management S.A. (0.96%) and Emerald Mutual Fund Advisers Trust (0.94%). Insiders that own company stock include Joseph Ciaffoni, Colleen Tupper, Shirley R Kuhlmann, Gino Santini, David Dieter, Scott Dreyer, Thomas B Smith, Rita J Balice-Gordon, Garen G Bohlin and John Gordon Freund.
View institutional ownership trends.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Collegium Pharmaceutical investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Arista Networks (ANET), Netflix (NFLX) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 2/26/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:COLL
• CIK: 1267565
• Web: www.collegiumpharma.com
• Phone: (781) 713-3699
• Fax: N/A
• Employees: 210
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Collegium Pharmaceutical: $53.40
• High Price Target: $60.00
• Low Price Target: $37.00
• Potential Upside/Downside: +52.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.71
• Trailing P/E Ratio: 20.40
• Forward P/E Ratio: 5.48
• P/E Growth: N/A
• Net Income: $62.87 million
• Net Margins: 8.05%
• Pretax Margin: 11.87%
• Return on Equity: 98.65%
• Return on Assets: 15.86%

Debt

• Debt-to-Equity Ratio: 2.59
• Current Ratio: 1.57
• Quick Ratio: 1.48

Sales & Book Value

• Annual Sales: $780.57 million
• Price / Sales: 1.45
• Cash Flow: $15.53 per share
• Price / Cash Flow: 2.25
• Book Value: $9.54 per share
• Price / Book: 3.66

Miscellaneous

• Outstanding Shares: 32,407,000
• Free Float: 31,807,000
• Market Cap: $1.13 billion
• Optionable: Optionable
• Beta: 0.76